The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2018 | Unmet therapy needs in cutaneous T-cell lymphoma
There are a high number of unmet needs in cutaneous T-cell lymphoma, as discussed here by Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Prof. Stadler highlights the need for novel therapies in the advanced setting, as well as topical therapies for early stage disease.
